Fig. 6.

Representative BLI of PyMT-BO1 GFP/Luc metastatic breast cancer cells in C57B6. a Untreated C57B6 mouse bearing highly metastatic PyMT-BO1 cancer. Accumulation in the lower limbs were predominant. b Mouse treated with 30 mg kg⁻¹ of HSA-TC nanoparticles. c Mouse treated with 800 µCi of ¹⁸FDG. d Mouse treated with a combination of HSA-TC and 800 µCi ¹⁸FDG. e Quantification of whole-body luminescence in CRIT-treated mice compared to untreated, HSA-TC treated or ¹⁸FDG-treated controls (*P values are 0.038, 0.23 and 0.017 for CRIT, HSA-TC alone and ¹⁸FDG alone, respectively). BLI and data analysis were performed on day 9 after initiation of PyMT-BO1 metastasis in mice. Studies were performed with n = 5 mice per each group